We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+20.26%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.39B
AUM Growth
+$536M
Cap. Flow
+$459M
Cap. Flow %
32.88%
Top 10 Hldgs %
64.45%
Holding
40
New
9
Increased
6
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$90.2M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$56M
3
DYAX
DYAX CORPORATION
DYAX
+$52.9M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$27.8M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$20M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$23.3M
2
TXMD icon
TherapeuticsMD
TXMD
+$11.6M
3
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$8.48M
4
ENZ
Enzo Biochem, Inc.
ENZ
+$6.62M
5
NVAX icon
Novavax
NVAX
+$4.88M

Sector Composition

Rank Sector Weight
1 Healthcare 58.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITMN
26
DELISTED
INTERMUNE INC
ITMN
$10.1M 0.72%
+300,801
New +$6.7M
ACHN
27
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$9.87M 0.71%
3,000,000
– –
FLXN
28
DELISTED
Flexion Therapeutics, Inc.
FLXN
$7.4M 0.53%
+450,000
New +$7.78M
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.51B
$6.08M 0.44%
250,000
-919,898
-79% -$23.3M
OCRX
30
DELISTED
Ocera Therapeutics, Inc.
OCRX
$5.57M 0.4%
527,797
-133,899
-20% -$1.91M
MGNX icon
31
MacroGenics
MGNX
$233M
$5.55M 0.4%
199,398
– –
ALIM
32
DELISTED
Alimera Sciences
ALIM
$5.26M 0.38%
+44,444
New +$4.32M
LITS
33
Lite Strategy Inc
LITS
$32.4M
$4.54M 0.33%
20,417
– –
DYAX
34
CALL
DELISTED
DYAX CORPORATION
DYAX
$4.49M 0.32%
500,000
– –
ATHE
35
CALL
Alterity Therapeutics
ATHE
$80.5M
$280K 0.02%
+1,667
New +$921K
FBIO icon
36
CALL
Fortress Biotech
FBIO
$111M
– –
-66,667
Closed -$2.63M
RMTI icon
37
PUT
Rockwell Medical
RMTI
$27.2M
– –
-9,091
Closed -$10.4M
ENZ
38
DELISTED
Enzo Biochem, Inc.
ENZ
– –
-2,268,653
Closed -$6.62M
LUMO
39
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-55,556
Closed -$11M
CHTP
40
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
– –
-666,667
Closed -$2.96M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, RA Capital Management held 40 positions worth $1.39B, up 62% from $858M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

RA Capital Management deployed $459M of net new capital in Q1 2014, opening 9 new positions and adding to 6 existing holdings. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 2,428,571 shares worth $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 73% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $23.3M trimmed.

  • RA Capital Management's largest Q1 2014 buy was Dicerna Pharmaceuticals, Inc.: 2,428,571 shares worth $68.6M.
  • RA Capital Management added most to DYAX CORPORATION in Q1 2014, an estimated $52.9M increase.
  • RA Capital Management's biggest Q1 2014 reduction was Acadia Pharmaceuticals, cutting an estimated $23.3M.
  • RA Capital Management fully exited Enzo Biochem, Inc. in Q1 2014, selling an estimated $6.62M.
  • RA Capital Management's ten largest holdings make up 64% of its $1.39B portfolio in Q1 2014.
  • RA Capital Management opened 9 new positions and closed 5 in Q1 2014.
  • RA Capital Management's portfolio value rose 62% quarter-over-quarter to $1.39B.

Based on RA Capital Management's 13F filing for Q1 2014, filed 15 May 2014.